Department of Neurology, Baylor College of Medicine, Houston, United States; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, United States
Emma C Thompson
Department of Neurology, Baylor College of Medicine, Houston, United States
Anuraag Madabushi
Department of Neurology, Baylor College of Medicine, Houston, United States
Department of Neurology, Children’s Colorado, University of Colorado, Aurora, United States; Department of Pediatrics, Children’s Colorado, University of Colorado, Aurora, United States
Heun Soh
Department of Physiology and Neurobiology, University of Connecticut, Storrs, United States
Nissi Varghese
Department of Physiology and Neurobiology, University of Connecticut, Storrs, United States
Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, United States
Kristen Springer
Department of Physiology and Neurobiology, University of Connecticut, Storrs, United States
Jim Johnson
KCNQ2 Cure Alliance, Denver, United States
Scotty Sims
KCNQ2 Cure Alliance, Denver, United States
Zhigang Ji
Department of Neurology, Baylor College of Medicine, Houston, United States
Ana G Chavez
Department of Neurology, Baylor College of Medicine, Houston, United States; Department of Neuroscience, Baylor College of Medicine, Houston, United States
Miranda J Jankovic
Department of Neurology, Baylor College of Medicine, Houston, United States
Bereket Habte
Department of Neurology, Children’s Colorado, University of Colorado, Aurora, United States; Department of Pediatrics, Children’s Colorado, University of Colorado, Aurora, United States
The Rare Disease Translational Center & Technology Evaluation and Development, The Jackson Laboratory, Bar Harbor, United States
Cathleen M Lutz
The Rare Disease Translational Center & Technology Evaluation and Development, The Jackson Laboratory, Bar Harbor, United States
Zhao Wang
Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, United States; CryoEM Core, Baylor College of Medicine, Houston, United States; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, United States
Vaishnav Krishnan
Department of Neurology, Baylor College of Medicine, Houston, United States; Department of Neuroscience, Baylor College of Medicine, Houston, United States; Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, United States
Lisa Dudler
Center for Human Genetics Tübingen, Tübingen, Germany
Stephanie Einsele-Scholz
Center for Human Genetics Tübingen, Tübingen, Germany
Jeffrey L Noebels
Department of Neurology, Baylor College of Medicine, Houston, United States; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, United States; Department of Neuroscience, Baylor College of Medicine, Houston, United States
Department of Neurology, Baylor College of Medicine, Houston, United States; Department of Neuroscience, Baylor College of Medicine, Houston, United States
Anastasios Tzingounis
Department of Physiology and Neurobiology, University of Connecticut, Storrs, United States
Department of Neurology, Baylor College of Medicine, Houston, United States; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, United States; Department of Neuroscience, Baylor College of Medicine, Houston, United States
KCNQ2 variants in children with neurodevelopmental impairment are difficult to assess due to their heterogeneity and unclear pathogenic mechanisms. We describe a child with neonatal-onset epilepsy, developmental impairment of intermediate severity, and KCNQ2 G256W heterozygosity. Analyzing prior KCNQ2 channel cryoelectron microscopy models revealed G256 as a node of an arch-shaped non-covalent bond network linking S5, the pore turret, and the ion path. Co-expression with G256W dominantly suppressed conduction by wild-type subunits in heterologous cells. Ezogabine partly reversed this suppression. Kcnq2G256W/+ mice have epilepsy leading to premature deaths. Hippocampal CA1 pyramidal cells from G256W/+ brain slices showed hyperexcitability. G256W/+ pyramidal cell KCNQ2 and KCNQ3 immunolabeling was significantly shifted from axon initial segments to neuronal somata. Despite normal mRNA levels, G256W/+ mouse KCNQ2 protein levels were reduced by about 50%. Our findings indicate that G256W pathogenicity results from multiplicative effects, including reductions in intrinsic conduction, subcellular targeting, and protein stability. These studies provide evidence for an unexpected and novel role for the KCNQ2 pore turret and introduce a valid animal model of KCNQ2 encephalopathy. Our results, spanning structure to behavior, may be broadly applicable because the majority of KCNQ2 encephalopathy patients share variants near the selectivity filter.